ARCHIVES

Motesanib Does Not Improve OS; Study Doesn’t Meet Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 4 | April 29, 2011

Download PDF Visit The Full Archive

Related Articles

NCI Plans Conference To Reconsider Breast Cancer Screening In women 40-49

April 19, 1996

Aromasin Approved By FDA For ER+ Early Breast Cancer

October 28, 2005

In Brief: NCI, OMB Heading For November Confrontation Over Hawaii, Papanicolaou Construction Funds

October 17, 1975

In Brief: Visco Elected Chairman of DOD Panel; Breast Cancer Stamp Raises $4.9 Million

February 19, 1999

CCIRC Reviews Two Existing, One Prospective Cooperative Group

March 4, 1977

Von Eschenbach says oncology is undergoing a “revolutionary evolution.”

May 20, 2005